CROSSROADS STRATEGIES, LLC for BRISTOL-MYERS SQUIBB
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
Issues related to pharmaceutical IP and supply chain; S.1260, United States Innovation and Competition Act of 2021.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SALIM ALAMEDDIN | — |
| JASON GLEASON | — |
| SHAY MICHAEL HANCOCK | — |
| MATHEW LAPINSKI | — |
| CHRIS J MILLER | — |
| HUNTER MOORHEAD | — |
| JASON BENJAMIN VAN PELT | — |
Taxation/Internal Revenue Code TAX
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
| Lobbyist | Covered position, as disclosed |
|---|---|
| SALIM ALAMEDDIN | — |
| JASON GLEASON | — |
| SHAY MICHAEL HANCOCK | — |
| MATHEW LAPINSKI | — |
| CHRIS J MILLER | — |
| HUNTER MOORHEAD | — |
| JASON BENJAMIN VAN PELT | — |
Copyright/Patent/Trademark CPT
Biopharmaceutical innovation and patent policy issues. Trademark legislative proposals. Bayh-Dole march-in rights policy issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SALIM ALAMEDDIN | — |
| JASON GLEASON | — |
| SHAY MICHAEL HANCOCK | — |
| MATHEW LAPINSKI | — |
| CHRIS J MILLER | — |
| HUNTER MOORHEAD | — |
| JASON BENJAMIN VAN PELT | — |
Budget/Appropriations BUD
FY2022 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act; H.R.748, CARES Act (P.L.116-136) implementation; H.R.133, Consolidated Appropriations Act, 2021 (P.L.116-260) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2); all bio-pharmaceutical related provisions.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SALIM ALAMEDDIN | — |
| JASON GLEASON | — |
| SHAY MICHAEL HANCOCK | — |
| MATHEW LAPINSKI | — |
| CHRIS J MILLER | — |
| HUNTER MOORHEAD | — |
| JASON BENJAMIN VAN PELT | — |
Health Issues HCR
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, and education around COVID-19 therapies. S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SALIM ALAMEDDIN | — |
| JASON GLEASON | — |
| SHAY MICHAEL HANCOCK | — |
| MATHEW LAPINSKI | — |
| CHRIS J MILLER | — |
| HUNTER MOORHEAD | — |
| JASON BENJAMIN VAN PELT | — |
Medicare/Medicaid MMM
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Proposed Part B IPI Demonstration Project; Drug Pricing; Medicaid rebates and AMP Cap; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2); H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes; H.R.3, Elijah E. Cummings Lower Drug Costs Now Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SALIM ALAMEDDIN | — |
| JASON GLEASON | — |
| SHAY MICHAEL HANCOCK | — |
| MATHEW LAPINSKI | — |
| CHRIS J MILLER | — |
| HUNTER MOORHEAD | — |
| JASON BENJAMIN VAN PELT | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.